The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

We’re encouraged to drink more water because ‘it’s good for us.’ Now, a new study has tested that claim, examining the evidence from previous studies to see whether increasing the amount of water you ...

Medical experts share their answers to all your questions on bladder problems, from urinary tract infections to odd urine ...

Many people believe that urinary tract infections (UTIs) and incontinence are more common in women, but they can also affect ...

Urination problems affect millions of men worldwide, often developing so gradually that many dismiss early warning signs.

The Food and Drug Administration (FDA) has approved Gemtesa ® (vibegron) for the treatment of overactive bladder (OAB ... is an important milestone for the men with unresolved symptoms of ...

The therapeutic response rate was 79% at 24 months, which is comparable to the rates seen at 6 months (78%) and 12 months (82%).

An overactive bladder can result from ... the National Academy of Medicine recommends women consume 2.7 liters (91 ounces) of fluids daily, and that men have 3.7 liters (125 ounces) daily.

An overactive bladder can result from hormonal issues ... Regarding hydration, the National Academy of Medicine recommends ...